CLOV News

(NASDAQ:CLOV) WASHINGTON, D.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) – Clover Health CEO Andrew Toy today had the honor to deliver testimony before the U.S. House of Representatives Committee on Energy and Commerce Subcommittee on Health, positioning Clover as a national leader in AI-enabled healthcare transformation. In his testimony, Andrew highlighted how Clover’s proprietary AI platform empowers physicians to deliver more personalized, timely care at the point of service, particularly to seniors in rural and other underserved communities. Motivated by a personal mission to improve care delivery following the loss of his father to complications from uncoordinated care, Andrew shared how Clover uses technology to simplify the healthcare experience and bring smarter, more proactive care to those who need it most.

Shares of Clover Health have surged 8.7% this week. The company reported Q1 results that highlighted rising profitability.

Clover Health Investments saw its shares jump more than 12% on Wednesday. Following better-than-expected profitability in the first-quarter, despite missing revenue estimates.

Almost all traders have had that moment: A confident stock pick or strategy that backfires and leaves the investor with less money than they had before and vowing never to trade that stock again.